Using viruses as nanomedicines

British Journal of Pharmacology

Volumn 171, Issue 17, 2014, Pages 4001-4009

  Van Kan Davelaar, H E ^a   Van Hest, J C M ^b   Cornelissen, J J L M ^a   Koay, M S T ^a  

^a UNIVERSITY OF TWENTE   (Netherlands)

^b RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC AGENT; DIAGNOSTIC AGENT; LIGAND; LIPOSOME; MACROGOL; NANOCARRIER; NANOPARTICLE; REAGENT; VIRUS PROTEIN; VIRUS RECEPTOR;

BACTERIAL INFECTION; BACTERIOPHAGE; BIODEGRADABILITY; BIOENGINEERING; CANCER THERAPY; COWPEA CHLOROTIC MOTTLE VIRUS; COWPEA MOSAIC VIRUS; CUCUMBER MOSAIC VIRUS; DRUG DELIVERY SYSTEM; FELINE PANLEUKOPENIA VIRUS; HOST CELL; HUMAN; IMMUNOPATHOLOGY; IMMUNOSTIMULATION; MOLECULAR DIAGNOSIS; MOLECULAR DIAGNOSTICS; MOLECULAR IMAGING; NANOIMAGING; NANOMEDICINE; NANOTECHNOLOGY; NONHUMAN; PLANT VIRUS; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; TISSUE DISTRIBUTION; VIRUS CAPSID; VIRUS CELL INTERACTION; VIRUS MORPHOLOGY; VIRUS PARTICLE; VIRUS STRAIN; VIRUS TRANSMISSION; CHEMISTRY; GENETIC ENGINEERING; GENETICS; IMMUNOLOGY; METABOLISM; PROCEDURES; VIRUS;

CAPSID; DRUG DELIVERY SYSTEMS; GENETIC ENGINEERING; HUMANS; LIGANDS; MOLECULAR IMAGING; NANOMEDICINE; VIRUSES;

EID: 84905982660     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12662     Document Type: Review

References (72)

1. Aarden L, Ruuls SR, Wolbink G, (2008). Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement. Curr Opin Immunol 20: 431-435.
2. Allen TM, Cullis PR, (2004). Drug delivery systems: entering the mainstream. Science 303: 1818-1822.
3. Bachmann MF, Jennings GT, (2011). Therapeutic vaccines for chronic diseases: successes and technical challenges. Philos Trans R Soc Lond B Biol Sci 366: 2815-2822.
4. Bardhan NM, Ghosh D, Belcher AM, (2013). M13 virus based detection of bacterial infections in living hosts. J Biophotonics. doi: 10.1002/jbio. 201300010. [Epub ahead of print].
5. Brasch M, de la Escosura A, Ma Y, Uetrecht C, Heck AJR, Torres T, et-al. (2011). Encapsulation of phthalocyanine supramolecular stacks into virus-like particles. J Am Chem Soc 133: 6878-6881.
6. Brasch M, Voets IK, Koay MST, Cornelissen JJLM, (2013). Phototriggered cargo release from virus-like assemblies. Faraday Discuss 166: 47-57.
7. Brunel FM, Lewis JD, Destito G, Steinmetz NF, Manchester M, Stuhlmann H, et-al. (2010). Hydrazone ligation strategy to assemble multifunctional viral nanoparticles for cell imaging and tumor targeting. Nano Lett 10: 1093-1097.
8. Carson L, Gorman SP, Gilmore BF, (2010). The use of lytic bacteriophages in the prevention and eradication of biofilms of Proteus mirabilis and Escherichia coli. FEMS Immunol Med Microbiol 59: 447-455.
9. Caruthers SD, Wickline SA, Lanza GM, (2007). Nanotechnological applications in medicine. Curr Opin Biotechnol 18: 26-30.
10. Chackerian B, Rangel M, Hunter Z, Peabody DS, (2006). Virus and virus-like particle-based immunogens for Alzheimer's disease induce antibody responses against amyloid-β without concomitant T cell responses. Vaccine 24: 6321-6331.
11. Chambers AF, Groom AC, MacDonald IC, (2002). Metastasis: dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2: 563-572.
12. Champion JA, Mitragotri S, (2006). Role of target geometry in phagocytosis. Proc Natl Acad Sci U S A 103: 4930-4934.
13. Chibeu A, Lingohr EJ, Masson L, Manges A, Harel J, Ackermann H-W, et-al. (2012). Bacteriophages with the ability to degrade uropathogenic Escherichia coli biofilms. Viruses 4: 471-487.
14. Costa L, Faustino MAF, Neves MGPMS, Cunha Â, Almeida A, (2012). Photodynamic inactivation of mammalian viruses and bacteriophages. Viruses 4: 1034-1074.
15. Damgé C, Michel C, Aprahamian M, Couvreur P, Devissaguet JP, (1990). Nanocapsules as carriers for oral peptide delivery. J Control Release 13: 233-239.
16. Destito G, Yeh R, Rae CS, Finn M, Manchester M, (2007). Folic acid-mediated targeting of cowpea mosaic virus particles to tumor cells. Chem Biol 14: 1152-1162.
17. Destito G, Schneemann A, Manchester M, (2009). Biomedical nanotechnology using virus-based nanoparticles. Curr Top Microbiol Immunol 327: 95-122.
18. Do TH, Chen Y, Nguyen VT, Phisitkul S, (2010). Vaccines in the management of hypertension. Expert Opin Biol Ther 10: 1077-1087.
19. Doane TL, Burda C, (2012). The unique role of nanoparticles in nanomedicine: imaging, drug delivery and therapy. Chem Soc Rev 41: 2885-2911.
20. Douglas T, Young M, (2006). Viruses: making friends with old foes. Science 312: 873-875.
21. Garnett MC, Kallinteri P, (2006). Nanomedicines and nanotoxicology: some physiological principles. Occup Med 56: 307-311.
22. Grasso S, Santi L, (2010). Viral nanoparticles as macromolecular devices for new therapeutic and pharmaceutical approaches. Int J Physiol Pathophysiol Pharmacol 2: 161-178.
23. Hodgson K, (2013). Bacteriophage therapy. Microbiol Aust 34: 28-31.
24. Hong S, Bielinska AU, Mecke A, Keszler B, Beals JL, Shi X, et-al. (2004). Interaction of poly(amidoamine) dendrimers with supported lipid bilayers and cells: hole formation and the relation to transport. Bioconjug Chem 15: 774-782.
25. Huang RK, Steinmetz NF, Fu C-Y, Manchester M, Johnson JE, (2011). Transferrin-mediated targeting of bacteriophage HK97 nanoparticles into tumor cells. Nanomedicine 6: 55-68.
26. Jennings GT, Bachmann MF, (2008). The coming of age of virus-like particle vaccines. Biol Chem 389: 521-536.
27. Jennings GT, Bachmann MF, (2009). Immunodrugs: therapeutic VLP-based vaccines for chronic diseases. Annu Rev Pharmacol Toxicol 49: 303-326.
28. Kaiser CR, Flenniken ML, Gillitzer E, Harmsen AL, Harmsen AG, Jutila MA, et-al. (2007). Biodistribution studies of protein cage nanoparticles demonstrate broad tissue distribution and rapid clearance in vivo. Int J Nanomedicine 2: 715-733.
29. Kaur T, Nafissi N, Wasfi O, Sheldon K, Wettig S, Slavcev R, (2012). Immunocompatibility of bacteriophages as nanomedicines. J Nanotechnol 2012: 1-13.
30. Klimek L, Willers J, Hammann-Haenni A, Pfaar O, Stocker H, Mueller P, et-al. (2011). Assessment of clinical efficacy of CYT003-QbG10 in patients with allergic rhinoconjunctivitis: a phase IIb study. Clin Exp Allergy 41: 1305-1312.
31. Koudelka KJ, Manchester M, (2010). The use of viruses in biomedical nanotechnology. Emerg Top Phys Virol 1: 289-312.
32. Lee LA, Wang Q, (2006). Adaptations of nanoscale viruses and other protein cages for medical applications. Nanomedicine 2: 137-149.
33. Leong HS, Steinmetz NF, Ablack A, Destito G, Zijlstra A, Stuhlmann H, et-al. (2010). Intravital imaging of embryonic and tumor neovasculature using viral nanoparticles. Nat Protoc 5: 1406-1417.
34. Lewis JD, Destito G, Zijlstra A, Gonzalez MJ, Quigley JP, Manchester M, et-al. (2006). Viral nanoparticles as tools for intravital vascular imaging. Nat Med 12: 354-360.
35. Li K, Nguyen HG, Lu X, Wang Q, (2010). Viruses and their potential in bioimaging and biosensing applications. Analyst 135: 21-27.
36. Lockney DM, Guenther RN, Loo L, Overton W, Antonelli R, Clark J, et-al. (2010). The red clover necrotic mosaic virus capsid as a multifunctional cell targeting plant viral nanoparticle. Bioconjug Chem 22: 67-73.
37. Ma Y, Nolte RJ, Cornelissen JJ, (2012). Virus-based nanocarriers for drug delivery. Adv Drug Deliv Rev 64: 811-825.
38. Mah T-FC, O'Toole GA, (2001). Mechanisms of biofilm resistance to antimicrobial agents. Trends Microbiol 9: 34-39.
39. Mendes JJ, Leandro C, Corte-Real S, Barbosa R, Cavaco-Silva P, Melo-Cristino J, et-al. (2013). Wound healing potential of topical bacteriophage therapy on diabetic cutaneous wounds. Wound Repair Regen 21: 595-603.
40. Moghimi SM, Hunter AC, Murray JC, (2005). Nanomedicine: current status and future prospects. FASEB J 19: 311-330.
41. Ochoa WF, Chatterji A, Lin T, Johnson JE, (2006). Generation and structural analysis of reactive empty particles derived from an icosahedral virus. Chem Biol 13: 771-778.
42. Rae CS, Wei Khor I, Wang Q, Destito G, Gonzalez MJ, Singh P, et-al. (2005). Systemic trafficking of plant virus nanoparticles in mice via the oral route. Virology 343: 224-235.
43. Ren Y, Wong SM, Lim L-Y, (2007). Folic acid-conjugated protein cages of a plant virus: a novel delivery platform for doxorubicin. Bioconjug Chem 18: 836-843.
44. Röhn TA, Bachmann MF, (2010). Vaccines against non-communicable diseases. Curr Opin Immunol 22: 391-396.
45. Saini V, Zharov VP, Brazel CS, Nikles DE, Johnson DT, Everts M, (2006). Combination of viral biology and nanotechnology: new applications in nanomedicine. Nanomedicine 2: 200-206.
46. Santi L, Huang Z, Mason H, (2006). Virus-like particles production in green plants. Methods 40: 66-76.
47. Saunders K, Sainsbury F, Lomonossoff GP, (2009). Efficient generation of cowpea mosaic virus empty virus-like particles by the proteolytic processing of precursors in insect cells and plants. Virology 393: 329-337.
48. Schroeder A, Heller DA, Winslow MM, Dahlman JE, Pratt GW, Langer R, et-al. (2012). Treating metastatic cancer with nanotechnology. Nat Rev Cancer 12: 39-50.
49. Seth AK, Geringer MR, Nguyen KT, Agnew SP, Dumanian Z, Galiano RD, et-al. (2013). Bacteriophage therapy for Staphylococcus aureus biofilm-infected wounds: a new approach to chronic wound care. Plast Reconstr Surg 131: 225-234.
50. Shriver LP, Koudelka KJ, Manchester M, (2009). Viral nanoparticles associate with regions of inflammation and blood brain barrier disruption during CNS infection. J Neuroimmunol 211: 66-72.
51. Singh P, Gonzalez MJ, Manchester M, (2006). Viruses and their uses in nanotechnology. Drug Dev Res 67: 23-41.
52. Singh P, Destito G, Schneemann A, Manchester M, (2006). Canine parvovirus-like particles, a novel nanomaterial for tumor targeting. J Nanobiotechnology 4: 1-11.
53. Singh P, Prasuhn D, Yeh RM, Destito G, Rae CS, Osborn K, et-al. (2007). Bio-distribution, toxicity and pathology of cowpea mosaic virus nanoparticles in vivo. J Control Release 120: 41-50.
54. Steinmetz NF, (2010). Viral nanoparticles as platforms for next-generation therapeutics and imaging devices. Nanomedicine 6: 634-641.
55. Steinmetz NF, Cho C-F, Ablack A, Lewis JD, Manchester M, (2011). Cowpea mosaic virus nanoparticles target surface vimentin on cancer cells. Nanomedicine 6: 351-364.
56. Steinmetz NF, Ablack AL, Hickey JL, Ablack J, Manocha B, Mymryk JS, et-al. (2011). Intravital imaging of human prostate cancer using viral nanoparticles targeted to gastrin-releasing peptide receptors. Small 7: 1664-1672.
57. Stephanopoulos N, Tong GJ, Hsiao SC, Francis MB, (2010). Dual-surface modified virus capsids for targeted delivery of photodynamic agents to cancer cells. ACS Na no 4: 6014-6020.
58. Suci PA, Varpness Z, Gillitzer E, Douglas T, Young M, (2007). Targeting and photodynamic killing of a microbial pathogen using protein cage architectures functionalized with a photosensitizer. Langmuir 23: 12280-12286.
59. Suci PA, Berglund DL, Liepold L, Brumfield S, Pitts B, Davison W, et-al. (2007). High-density targeting of a viral multifunctional nanoplatform to a pathogenic, biofilm-forming bacterium. Chem Biol 14: 387-398.
60. Takeichi M, (1990). Cadherins: a molecular family important in selective cell-cell adhesion. Annu Rev Biochem 59: 237-252.
61. Takemura-Uchiyama I, Uchiyama J, Kato S, Inoue T, Ujihara T, Ohara N, et-al. (2013). Evaluating efficacy of bacteriophage therapy against Staphylococcus aureus infections using a silkworm larval infection model. FEMS Microbiol Lett 347: 52-60.
62. Tong GJ, Hsiao SC, Carrico ZM, Francis MB, (2009). Viral capsid DNA aptamer conjugates as multivalent cell-targeting vehicles. J Am Chem Soc 131: 11174-11178.
63. Vandenheuvel D, Singh A, Vandersteegen K, Klumpp J, Lavigne R, Van den Mooter G, (2013). Feasibility of spray drying bacteriophages into respirable powders to combat pulmonary bacterial infections. Eur J Pharm Biopharm 84: 578-582.
64. Wainwright M, Crossley KB, (2004). Photosensitising agents-circumventing resistance and breaking down biofilms: a review. Int Biodeterior Biodegradation 53: 119-126.
65. Wells CL, Maddaus MA, Erlandsen SL, Simmons RL, (1988). Evidence for the phagocytic transport of intestinal particles in dogs and rats. Infect Immun 56: 278-282.
66. Wen AM, Rambhia PH, French RH, Steinmetz NF, (2013). Design rules for nanomedical engineering: from physical virology to the applications of virus-based materials in medicine. J Biol Phys 39: 1-25.
67. Yacoby I, Shamis M, Bar H, Shabat D, Benhar I, (2006). Targeting antibacterial agents by using drug-carrying filamentous bacteriophages. Antimicrob. Agents Chemother 50: 2087-2097.
68. Yacoby I, Bar H, Benhar I, (2007). Targeted drug-carrying bacteriophages as antibacterial nanomedicines. Antimicrob Agents Chemother 51: 2156-2163.
69. Yildiz I, Shukla S, Steinmetz NF, (2011). Applications of viral nanoparticles in medicine. Curr Opin Biotechnol 22: 901-908.
70. Yildiz I, Tsvetkova I, Wen AM, Shukla S, Masarapu MH, Dragnea B, et-al. (2012). Engineering of Brome mosaic virus for biomedical applications. RSC Advances 2: 3670-3677.
71. Yilmaz C, Colak M, Yilmaz BC, Ersoz G, Kutateladze M, Gozlugol M, (2013). Bacteriophage therapy in implant-related infections: an experimental study. J Bone Joint Surg Am 95: 117-125.
72. Zeng Q, Wen H, Wen Q, Chen X, Wang Y, Xuan W, et-al. (2013). Cucumber mosaic virus as drug delivery vehicle for doxorubicin. Biomaterials 34: 4632-4642.